Crescent Biopharma, Inc. (CBIO)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
CBIO votes on board directors, auditors, and compensation at annual meeting
# 🧾 What This Document Is 📜 This is a Proxy Statement (Schedule 14A), which is a critical legal filing used by companies to gather votes from their shareholders. It outlines the major business and governance decisions that shareholders are expected to vote on at the company’s Annual General Meetin
SEC filings
All filings →Insider trades
All insider trades →Crescent Biopharma, Inc. has no reported insider trades in the last 90 days.